Latest News and Press Releases
Want to stay updated on the latest news?
-
Activation of multiple inflammasome pathways and extracellular ASC specks contribute to development and progression of common neurological diseases.
-
Inflammation resulting from activation of more than one type inflammasome and ASC specks contribute to development and progression of neurological disease
-
ZyVersa CEO will discuss development milestones for Cholesterol Efflux Mediator VAR 200 and Inflammasome ASC Inhibitor IC 100 at BIO CEO & Investor Conf.
-
NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications (e.g., Type 2 Diabetes, Hypertension, Heart Disease).
-
Activation of the inflammasome/ASC speck pathway has a vital role in synaptic degeneration in Alzheimer’s Disease (AD).
-
NLRP3 Inflammasome Activation Is Linked to Brain Metastasis in Patients with Triple-Negative Breast Cancer.
-
View ZyVersa Therapeutics' Benzinga All Access Interview To Learn About Key Development Milestones in 2024.
-
ZyVersa is developing two proprietary product platforms targeting renal and inflammatory diseases. Cholesterol Efflux MediatorTM VAR 200, designed to ameliorate renal lipid accumulation that...
-
WESTON, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for...
-
WESTON, Fla., Dec. 18, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for...